Literature DB >> 17075983

Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure.

Kazuhiro Kotoh1, Munechika Enjoji, Makoto Nakamuta, Tsuyoshi Yoshimoto, Motoyuki Kohjima, Shusuke Morizono, Shinsaku Yamashita, Yuki Horikawa, Kengo Yoshimitsu, Tsuyoshi Tajima, Yoshiki Asayama, Kousei Ishigami, Masakazu Hirakawa.   

Abstract

AIM: To utilize transcatheter arterial steroid injection therapy (TASIT) via the hepatic artery to reduce hepatic macrophage activity in patients with severe acute hepatic failure.
METHODS: Thirty-four patients with severe acute hepatic failure were admitted to our hospital between June 2002 to June 2006 providing for the possibility of liver transplantation (LT). Seventeen patients were treated using traditional liver supportive procedures, and the other 17 patients additionally underwent TASIT with 1000 mg methylprednisolone per day for 3 continuous days.
RESULTS: Of the 17 patients who received TASIT, 13 were cured without any complications, 2 died, and 2 underwent LT. Of the 17 patients who did not receive TASIT, 4 were self-limiting, 7 died, and 6 underwent LT. Univariate logistic analysis revealed that ascites, serum albumin, prothrombin time, platelet count, and TASIT were significant variables for predicating the prognosis. Multivariate logistic regression analysis using stepwise variable selection showed that prothrombin time, platelet count, and TASIT were independent predictive factors.
CONCLUSION: TASIT might effectively prevent the progression of severe acute hepatic failure to a fatal stage of fulminant liver failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075983      PMCID: PMC4125675          DOI: 10.3748/wjg.v12.i41.6678

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  A prospective trial of steroid therapy in severe viral hepatitis. The prognostic significance of bridging necrosis.

Authors:  A J Ware; J A Cuthbert; J Shorey; L E Gurian; E H Eigenbrodt; B Combes
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

2.  A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group.

Authors:  J Rakela; J W Mosley; V M Edwards; S Govindarajan; E Alpert
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

3.  Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure.

Authors:  H Sekido; K Matsuo; K Takeda; M Ueda; D Morioka; T Kubota; K Tanaka; I Endo; S Togo; H Shimada
Journal:  Transplant Proc       Date:  2004-10       Impact factor: 1.066

4.  Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey.

Authors:  Shunichi Sato; Kazuyuki Suzuki; Yasuhiro Takikawa; Ryujin Endo; Masao Omata
Journal:  Hepatol Res       Date:  2004-11       Impact factor: 4.288

5.  Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure.

Authors:  A Davenport; E J Will; A M Davison
Journal:  Kidney Int Suppl       Date:  1993-06       Impact factor: 10.545

6.  Prediction of hepatic encephalopathy development in patients with severe acute hepatitis.

Authors:  Yasuhiro Takikawa; Ryujin Endo; Kazuyuki Suzuki; Kenji Fujiwara; Masao Omata
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

7.  Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure.

Authors:  Konstantinos J Dabos; Philip N Newsome; John A Parkinson; Hazem H Mohammed; Ian H Sadler; John N Plevris; Peter C Hayes
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

8.  Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma.

Authors:  Hiroaki Tanioka; Akihito Tsuji; Sojiro Morita; Tadashi Horimi; Masahiro Takamatsu; Tetsuhiko Shirasaka; Takaaki Mizushima; Koji Ochi; Katsuyuki Kiura; Mitsune Tanimoto
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

9.  Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis.

Authors:  A Theodossi; A L Eddleston; R Williams
Journal:  Gut       Date:  1982-01       Impact factor: 23.059

10.  Glucocorticoid suppression of macrophage migration inhibitory factor.

Authors:  J E Balow; A S Rosenthal
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

View more
  9 in total

1.  A new treatment strategy for acute liver failure.

Authors:  Kazuhiro Kotoh; Masaki Kato; Motoyuki Kohjima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Hepatol       Date:  2010-11-27

2.  Antithrombin III injection via the portal vein suppresses liver damage.

Authors:  Masayuki Miyazaki; Masaki Kato; Masatake Tanaka; Kosuke Tanaka; Shinichiro Takao; Motoyuki Kohjima; Tetsuhide Ito; Munechika Enjoji; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

3.  Hepatoprotective potential of new steroid against carbon tetrachloride-induced hepatic injury.

Authors:  Muhammad Afzal; Ruqaiyah Khan; Imran Kazmi; Firoz Anwar
Journal:  Mol Cell Biochem       Date:  2013-03-20       Impact factor: 3.396

4.  Hemodynamic Alteration in the Liver in Acute Hepatitis: A Quantitative Evaluation Using Computed Tomographic Perfusion.

Authors:  Akihiro Nishie; Yasuhiro Ushijima; Yukihisa Takayama; Nobuhiro Fujita; Yuichiro Kubo; Keisuke Ishimatsu; Daisuke Tsurumaru; Motoyuki Kohjima; Kousei Ishigami
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 5.  Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?

Authors:  Mohamed M A Zaitoun; Mohammad Abd Alkhalik Basha; Ali Hassan Elmokadem
Journal:  Eur Radiol Exp       Date:  2020-07-06

Review 6.  The Management of Glucocorticoid Therapy in Liver Failure.

Authors:  Ran Xue; Qinghua Meng
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

Review 7.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

8.  What's new in acute liver failure?

Authors:  Christine Bernsmeier; Charalambos G Antoniades; Julia Wendon
Journal:  Intensive Care Med       Date:  2014-07-01       Impact factor: 17.440

9.  Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: A systematic review and meta-analysis.

Authors:  Ranran Gao; Yang Li; Yang Cao; Rongjiong Zheng; Li Tang; Jianzhong Yang; Xiaobo Lu
Journal:  Medicine (Baltimore)       Date:  2020-06-19       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.